289 related articles for article (PubMed ID: 23380533)
21. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.
Liu WG; Lu GQ; Li B; Chen SD
Parkinsonism Relat Disord; 2007 Mar; 13(2):77-88. PubMed ID: 16963309
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
24. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
[TBL] [Abstract][Full Text] [Related]
25. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
26. Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Olds ME; Jacques DB; Kopyov O
Synapse; 2005 Jan; 55(1):26-36. PubMed ID: 15499610
[TBL] [Abstract][Full Text] [Related]
27. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).
Kirkeby A; Torup L; Bochsen L; Kjalke M; Abel K; Theilgaard-Monch K; Johansson PI; Bjørn SE; Gerwien J; Leist M
Thromb Haemost; 2008 Apr; 99(4):720-8. PubMed ID: 18392330
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
Vernon AC; Palmer S; Datla KP; Zbarsky V; Croucher MJ; Dexter DT
Eur J Neurosci; 2005 Oct; 22(7):1799-806. PubMed ID: 16197521
[TBL] [Abstract][Full Text] [Related]
29. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease.
Singh S; Ahmad R; Mathur D; Sagar RK; Krishana B
Indian J Exp Biol; 2006 Sep; 44(9):699-704. PubMed ID: 16999024
[TBL] [Abstract][Full Text] [Related]
31. Role of L-thyroxin in counteracting rotenone induced neurotoxicity in rats.
Salama M; Helmy B; El-Gamal M; Reda A; Ellaithy A; Tantawy D; Mohamed M; El-Gamal A; Sheashaa H; Sobh M
Environ Toxicol Pharmacol; 2013 Mar; 35(2):270-7. PubMed ID: 23357603
[TBL] [Abstract][Full Text] [Related]
32. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotection with or without erythropoiesis; sometimes less is more.
Torup L
Br J Pharmacol; 2007 Aug; 151(8):1141-2. PubMed ID: 17533424
[TBL] [Abstract][Full Text] [Related]
34. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease.
Garbayo E; Ansorena E; Lanciego JL; Blanco-Prieto MJ; Aymerich MS
Mov Disord; 2011 Aug; 26(10):1943-7. PubMed ID: 21661048
[TBL] [Abstract][Full Text] [Related]
35. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
[TBL] [Abstract][Full Text] [Related]
36. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis.
Savino C; Pedotti R; Baggi F; Ubiali F; Gallo B; Nava S; Bigini P; Barbera S; Fumagalli E; Mennini T; Vezzani A; Rizzi M; Coleman T; Cerami A; Brines M; Ghezzi P; Bianchi R
J Neuroimmunol; 2006 Mar; 172(1-2):27-37. PubMed ID: 16337691
[TBL] [Abstract][Full Text] [Related]
37. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
38. Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease.
Walsh S; Gavin A; Wyatt S; O'Connor C; Keeshan K; Nolan YM; O'Keeffe GW; Sullivan AM
Int J Neurosci; 2015 Jan; 125(1):70-7. PubMed ID: 24628580
[TBL] [Abstract][Full Text] [Related]
39. Effect of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) on learning and memory impairment and hippocampal apoptosis induced by intracerebroventricular administration of streptozotocin in rats.
Moosavi M; Hooshmandi E; Javadpour P; Maghsoudi N; Katinger H; Ghasemi R
Behav Brain Res; 2020 Apr; 384():112554. PubMed ID: 32057828
[TBL] [Abstract][Full Text] [Related]
40. BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson's disease.
Real CC; Ferreira AF; Chaves-Kirsten GP; Torrão AS; Pires RS; Britto LR
Neuroscience; 2013 May; 237():118-29. PubMed ID: 23396085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
